Aptorum Group Limited
APM
|
$5.69
3.45%
3.34%
17K
|
Health Technology
(0.0% 1d) (-37.2% 1m) (91.7% 1y) (0.0% 2d) (1.1% 3d) (-3.3% 7d) (-44.17% volume)
Earnings Calendar:
Market Cap: $ 9,784,080
http://www.aptorumgroup.com
Sec Filling | Patents | 37 employees
Aptorum Group Ltd. is a pharmaceutical company dedicated to the discovery, development and commercializing of therapeutic assets to treat diseases with unmet medical needs, particularly infectious diseases and cancers. It operates through the Therapeutics and Non-Therapeutics segments. The Therapeutics segment seeks to develop various drug molecules and certain technologies for the treatment and diagnosis of human disease conditions in neurology, infectious diseases, gastroenterology, oncology, metabolic disorders, women's health and other disease areas. The Non-Therapeutics segment encompasses the development of surgical robotics and medical devices; operates the activities of AML Clinic; and sale of natural supplement. The firm’s pipe line is enriched through the establishment of drug discovery platforms that enable the discovery of new therapeutics assets. It also has projects focused on natural supplement for women undergoing menopause and experiencing related symptoms. The company was founded by Ian Huen on September 13, 2010 and is headquartered in London, the United Kingdom.
cancer infectious disease surgical robotics urea women health drug discovery metabolic women diagnostics neurological treatment
add to watch list Paper trade email alert is off
Press-releases
Aptorum Group Receives Nasdaq Approval to Transfer Listing to Nasdaq Capital Markets
Published: 2023-08-10 (Crawled : 09:00) - biospace.com/
APM | $5.69 3.45% 3.34% 17K
|
Health Technology
|
| O: 3.54%
H: 1.95%
C: -5.86%
nasdaq transfer approval group
Aptorum Group Updates on a Phase 1b/2a Clinical Trial for Repurposed Small Molecule Drug SACT-1 for Neuroblastoma
Published: 2023-06-22 (Crawled : 13:00) - biospace.com/
APM | $5.69 3.45% 3.34% 17K
|
Health Technology
|
| O: 0.73%
H: 0.36%
C: -1.81%
drug repurposed group trial
Aptorum Therapeutics Limited Enters Into Letter of Intent and Term Sheet with Universal Sequencing Technology Corporation to Merge with Aptorum Group’s Subsidiary Paths Innovations Limited
Published: 2023-05-01 (Crawled : 13:00) - biospace.com/
APM | $5.69 3.45% 3.34% 17K
|
Health Technology
|
| O: 10.67%
H: 0.0%
C: -4.64%
universal corporation technology therapeutics merge
Aptorum Group Announces Completion of Pre-IND Discussions with US FDA on its ALS-4, a First-in-Class Small Molecule Drug Targeting Methicillin Resistant Staphylococcus Aureus
Published: 2023-03-03 (Crawled : 14:00) - biospace.com/
APM | $5.69 3.45% 3.34% 17K
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: -2.23%
fda drug group staphylococcus aureus
Aptorum Group Announces Completion of End of Phase 1 (EOP1) Meeting with US FDA on its SACT-1, a Repurposed Small Molecule Drug Targeting Neuroblastoma
Published: 2023-03-03 (Crawled : 14:00) - biospace.com/
APM | $5.69 3.45% 3.34% 17K
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: -2.23%
fda drug meeting repurposed group phase 1
Aptorum Group Announces 1-for-10 Reverse Stock Split
Published: 2023-01-20 (Crawled : 14:00) - biospace.com/
APM | $5.69 3.45% 3.34% 17K
|
Health Technology
|
| O: -3.51%
H: 18.18%
C: 1.82%
group
Aptorum Group Limited Announces Results of 2022 Annual General Meeting of Shareholders
Published: 2022-12-22 (Crawled : 13:20) - biospace.com/
APM | $5.69 3.45% 3.34% 17K
|
Health Technology
|
| O: 4.95%
H: 10.92%
C: 2.25%
meeting results group
Aptorum Group Announces Offering of $3 Million Convertible Note due 2023
Published: 2022-12-09 (Crawled : 13:00) - biospace.com/
APM | $5.69 3.45% 3.34% 17K
|
Health Technology
|
| O: -16.14%
H: 19.24%
C: 14.67%
offering group
Myriad Genetics Patient Outcomes Study Shows RiskScore Leads to More Accurate Breast Cancer Risk Prediction than Standard-of-Care Risk Model Myriad Genetics, Inc., a leader in genetic testing and preci...
Published: 2022-12-09 (Crawled : 13:00) - biospace.com/
SXT | $70.03 0.2% 0.0% 1.3M
|
Distribution Services
|
| O: -0.42%
H: 0.97%
C: -0.33%
PFE | News 4 | $26.27 -0.19% -0.15% 23M
|
Health Technology
|
| O: -0.06%
H: 2.11%
C: -0.06%
TRIB | $1.83 -3.87% 11K
|
Health Technology
|
| O: -1.56%
H: 1.58%
C: -1.75%
REPL | $6.32 -1.56% -1.58% 630K
|
Health Technology
|
| O: -0.25%
H: 5.25%
C: 4.17%
MYGN | $18.61 0.05% 0.05% 480K
|
Health Technology
|
| O: -0.67%
H: 1.39%
C: -2.69%
IMGN | News | $31.23 0.03% 49M
|
Health Technology
|
| O: -0.19%
H: 0.77%
C: -0.77%
GILD | $67.07 0.06% 0.06% 8.3M
|
Health Technology
|
| O: -0.23%
H: 0.0%
C: -1.45%
BNTX | News | $88.18 -0.35% -0.35% 280K
|
Health Technology
|
| O: -0.05%
H: 0.75%
C: -0.83%
APM | $5.69 3.45% 3.34% 17K
|
Health Technology
|
| O: -16.14%
H: 19.24%
C: 14.67%
risk breast genetic cancer study
Aptorum Announces Publication of a Sensitive Liquid Chromatography with Time-Of-Flight Mass Spectrometry Assay for In Vivo Pharmacokinetic Study of Epigallocatechin-gallate octaacetate (Pro-EGCG)
Published: 2022-11-25 (Crawled : 17:00) - biospace.com/
APM | $5.69 3.45% 3.34% 17K
|
Health Technology
|
| O: -5.69%
H: 6.01%
C: 5.7%
publication study
Last 15 days Sec forms
| File Id | Form | Published Date | Transaction Date | Direction | Code | Amount Transacted | Owned Amount |
Your Today's Watch List
Sign in to create a watchlistGainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Last 48 Hours Insiders Buying
RKT P 347 | $12.55 -0.63% 0.48% 1.7M
|
Finance
|
22:30
NWFL | News | $24.6 2.03% 1.99% 9.9K
|
Finance
|
22:00
TGEN P 10000 | $0.685 39.71% 6.6K
|
Utilities
|
20:01
MNSB P 310 | $15.88 -2.93% -3.02% 46K
|
Finance
|
15:30
RMCF | $3.54 0.28% 7.1K
|
Consumer Non-Durables
|
20:10